Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
· Favorable safety profile and effective biochemical control in 52-week trial · Significant improvement of acromegaly symptoms vs. standard of care at baseline · Improved patient reported treatment satisfaction, convenience, and quality of life Lund, Sweden — 17 July 2023 — Camurus (NASDAQ STO: CAMX) today announced topline, interim data from an open-label, long-term safety and extension trial, ACROINNOVA 2, assessing CAM2029, octreotide subcutaneous (SC) depot, in 135 adult patients with acromegaly. These include both new patients and roll-over patients from the previous